| Literature DB >> 29655451 |
Michael H Rivner1, Mamatha Pasnoor2, Mazen M Dimachkie3, Richard J Barohn4, Lin Mei5.
Abstract
Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.Entities:
Keywords: Agrin; Cortactin; LRP4; MuSK; Myasthenia gravis; Rapsyn
Mesh:
Substances:
Year: 2018 PMID: 29655451 PMCID: PMC6051709 DOI: 10.1016/j.ncl.2018.01.004
Source DB: PubMed Journal: Neurol Clin ISSN: 0733-8619 Impact factor: 3.806